The goal of this clinical trial is to evaluate the immunogenicity and safety of booster immunization of varicella live attenuated vaccine (varicella vaccine hereafter) at different intervals.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
412
lyophilized powder, subcutaneous injection
Jiangsu Provincial Center for Disease control and Prevention
Nanjing, Jiangsu, China
Geometric mean titer (GMT) of varicella-zoster virus (VZV) antibodies
GMT of VZV antibodies 30 days after booster dose immunization
Time frame: 30 days after booster dose immunization
Seroconversion rate of varicella-zoster virus (VZV) antibodies
Seroconversion rate of VZV antibodies 30 days after booster dose immunization
Time frame: 30 days after booster dose immunization
Seropositive rate of varicella-zoster virus (VZV) antibodies
Seropositive rate of VZV antibodies 30 days after booster dose immunization
Time frame: 30 days after booster dose immunization
Geometric mean increase (GMI) of varicella-zoster virus (VZV) antibodies
GMI of VZV antibodies 30 days after booster dose immunization
Time frame: 30 days after booster dose immunization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.